Alnylam Pharmaceuticals Executive and Leadership Team

Yvonne Greenstreet, the Chief Executive Officer at Alnylam Pharmaceuticals, directs the company's overall strategy and operational execution. Greenstreet guides the advancement of RNAi therapeutics, focusing on the discovery, development, and commercialization of novel treatments for rare genetic, cardio-metabolic, and hepatic infectious diseases. Overseeing global operations, the Chief Executive Officer ensures alignment with corporate objectives and market demands. This leadership role involves driving innovation in the biopharmaceutical sector and expanding market reach for Alnylam's innovative product portfolio, including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. By fostering strategic collaborations and optimizing research pipelines, Yvonne Greenstreet directly impacts the company's growth and its mission to transform patient lives. Ultimately, Greenstreet secures long-term financial stability and market leadership.

Jeffrey Poulton, the Chief Financial Officer at Alnylam Pharmaceuticals, manages the company's financial strategy and fiscal operations. Poulton oversees all aspects of financial planning, budgeting, accounting, and investor relations, ensuring robust financial health and sustainable growth. This critical role involves securing capital for research and development initiatives, managing corporate investments, and optimizing financial performance across global operations. By providing strategic financial insights, the Chief Financial Officer supports executive decision-making and guides the company's resource allocation to maximize the impact of its therapeutic pipeline. Jeffrey Poulton's expertise is vital for navigating the complex financial landscape of the biopharmaceutical industry and achieving Alnylam's long-term objectives.

Vasant Jadhav, the Chief Technology Officer at Alnylam Pharmaceuticals, architects the company's technological infrastructure and innovation pipeline. Jadhav oversees the development and implementation of cutting-edge technologies essential for discovering and developing novel RNAi therapeutics. This role involves managing research and development platforms, ensuring the scalability and efficiency of manufacturing processes, and driving technological advancements in areas like drug delivery and genetic sequencing. By integrating advanced computational tools and data analytics, the Chief Technology Officer enhances the precision and speed of therapeutic development. Vasant Jadhav's leadership ensures Alnylam maintains its technological edge in the competitive biopharmaceutical landscape, supporting the company's mission to create life-changing medicines.

Shweta Randeria, the Chief Marketing Officer at Alnylam Pharmaceuticals, spearheads the commercialization strategies for the company's innovative RNAi therapeutics. Randeria directs market analysis, product positioning, and promotional campaigns to effectively reach patients and healthcare providers. This leadership position involves developing comprehensive go-to-market plans for new drug launches and expanding the reach of existing therapies like ONPATTRO and AMVUTTRA. By understanding market dynamics and patient needs, the Chief Marketing Officer ensures Alnylam's treatments gain widespread adoption and accessibility. Shweta Randeria's strategic vision drives market penetration and reinforces Alnylam's position as a leader in RNAi therapeutics.

Danielle Dougherty, the Manager, Chief Marketing Officer Management at Alnylam Pharmaceuticals, supports the strategic execution of marketing initiatives. Dougherty facilitates the coordination of cross-functional teams to ensure seamless implementation of commercial strategies for Alnylam's RNAi therapeutics. This role involves managing project timelines, coordinating communication between marketing, sales, and R&D departments, and ensuring alignment with the Chief Marketing Officer's vision. By optimizing internal processes and providing essential operational support, the Manager, Chief Marketing Officer Management enhances the efficiency of marketing operations. Danielle Dougherty's contributions are key to driving market success and expanding patient access to Alnylam's innovative treatments.

Carlo Cristobal, the Head To of & Ttr Franchise Chief of Staff (US) at Alnylam Pharmaceuticals, drives strategic initiatives and operational excellence for the TTR franchise within the United States. Cristobal coordinates cross-functional efforts to advance the development and commercialization of therapies targeting transthyretin amyloidosis (ATTR). This role involves managing key projects, facilitating communication between leadership and operational teams, and ensuring strategic alignment across all US-based activities for the TTR franchise. By optimizing resource allocation and streamlining workflows, the Head To of & Ttr Franchise Chief of Staff (US) enhances the franchise's ability to meet market demands and patient needs. Carlo Cristobal's leadership ensures the successful execution of Alnylam's TTR-focused strategy in the US market.

Melissa McLaughlin, the Chief Human Resources Officer at Alnylam Pharmaceuticals, leads the company's talent strategy and organizational development. McLaughlin oversees all human resources functions, including talent acquisition, employee engagement, compensation and benefits, and organizational culture initiatives. This role is crucial for attracting, developing, and retaining the highly skilled workforce necessary to drive innovation in RNAi therapeutics. By fostering a supportive and high-performance work environment, the Chief Human Resources Officer ensures Alnylam has the talent needed to achieve its ambitious goals. Melissa McLaughlin's leadership cultivates a culture of excellence and collaboration, essential for the company's continued success and scientific breakthroughs.

Bryan Supran, the Chief Legal Officer at Alnylam Pharmaceuticals, directs the company's legal affairs and ensures compliance with all regulatory requirements. Supran oversees intellectual property strategy, corporate governance, litigation, and contract negotiations, safeguarding Alnylam's interests globally. This position is vital for navigating the complex legal and regulatory landscape inherent in the biopharmaceutical industry, particularly concerning novel RNAi therapeutics. By providing expert legal counsel, the Chief Legal Officer supports strategic decision-making and mitigates potential risks. Bryan Supran's guidance is instrumental in protecting Alnylam's innovations and facilitating its continued growth and market expansion.